Suchergebnisse - "Sankar, Kamya"

PubPharm (37)

1

Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer

enthalten in: International journal of radiation oncology, biology, physics | 2024

von Edwards, D. | Sankar, K. | Alseri, A. | +10

2

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC : A Multicenter Retrospective Cohort Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Nassar, A. | Kim, S. | Aredo, J. | +54

3

Recent advances in the management of hepatocellular carcinoma

enthalten in: Clinical and molecular hepatology | 2024

von Sankar, K. | Gong, J. | Osipov, A. | +6

4

Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma

enthalten in: The American journal of gastroenterology | 2023

von Yeo, Y. | Liang, J. | Lauzon, M. | +16

5

TOPAZ-1 : a new standard of care for advanced biliary tract cancers?

enthalten in: Immunotherapy | 2023

von Ebia, M. | Sankar, K. | Osipov, A. | +2

6

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma

enthalten in: International journal of molecular sciences | 2023

von Ji, J. | Ha, S. | Lee, D. | +4

7

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

enthalten in: Cancer cell | 2023

von Li, G. | Choi, J. | Kryczek, I. | +24

CommentIn: Cancer Cell. 2023 Feb 13;41(2):229-231. - PMID 36787694

8

Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers

enthalten in: Translational gastroenterology and hepatology | 2023

von Sankar, K. | Pearson, A. | Worlikar, T. | +6

9

Approach to systemic therapy in advanced hepatocellular carcinoma

enthalten in: Hepatobiliary surgery and nutrition | 2022

von Sankar, K. | Gong, J. | Kosari, K. | +2

CommentOn: J Hepatol. 2021 Oct;75(4):960-974. - PMID 34256065

10

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations

enthalten in: Expert opinion on pharmacotherapy | 2022

von Strohbehn, G. | Sankar, K. | Qin, A. | +1